Introduction {#S5}
============

Lisdexamfetamine dimesylate (LDX) is a long-acting pro-drug psychostimulant indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children (6--12 years of age), adolescents (13--17 years of age), and in adults. LDX is a therapeutically inactive molecule. After oral ingestion, it is absorbed as the intact pro-drug and then enzymatically hydrolyzed to l-lysine and active d-amphetamine, which is responsible for the therapeutic effect^[@C1]^. The pharmacokinetic characteristics of LDX permit once-daily dosing^[@C2]^. Plasma concentrations of d-amphetamine peak at ∼3.0--5.0 h after oral LDX dosing, with a half-life of ∼9.0--10.0 h^[@C2],[@C3]^. The process of LDX biotransformation by red blood cells (RBCs) controls the rate of d-amphetamine delivery, unlike other long-acting psychostimulant formulations in which extended activity is dependent on slow tablet dissolution or medication release within the gastrointestinal tract^[@C1]^.

The d-amphetamine plasma concentration-time profile is linear and dose proportional and exhibits low inter- and intra-patient variability^[@C3],[@C4]^. Moreover, the pharmacokinetic profile of d-amphetamine is relatively similar, regardless of whether LDX is administered orally, intra-nasally, or intravenously^[@C5],[@C6]^.

Although it has been erroneously reported that LDX is hydrolyzed in gastrointestinal fluids^[@C7]^, the primary site of hydrolytic metabolism of LDX to d-amphetamine is the RBC, but not other human blood fractions^[@C1]^. The mechanisms by which RBCs carry out such metabolism are currently being evaluated. RBC-mediated LDX metabolism is robust; the metabolism rate slowly declined with increased dilution, yet was still substantial even when RBC concentrations are reduced to only 10% of normal values^[@C1]^. It is not known, however, whether the enzymatic metabolism of LDX occurs on the RBC membrane or within the cell interior. Moreover, the enzyme(s) responsible for the metabolism have not been identified. Peptidases present in RBCs may be candidates for mediating the catalysis of LDX^[@C8]^. Given the primary role of RBCs in the hydrolytic metabolism of LDX to d-amphetamine, it is unknown whether pathologic conditions that affect RBCs, such as sickle cell disease, would have an effect on LDX hydrolysis and the resulting pharmacokinetic profile of d-amphetamine. Abnormalities of RBC function that occur in sickle cell disease may affect protein structure and function within an interactive network of RBC proteins^[@C8]^.

More detailed information regarding the transport and enzymatic hydrolysis of LDX to d-amphetamine is needed. These *in vitro* studies examined whether enzymatic metabolism of LDX differed in human whole blood samples from healthy donors vs those with sickle cell disease.

Patients and methods {#S6}
====================

Blood samples {#S0006-S2001}
-------------

### RBCs {#S0006-S2001-S3001}

Whole blood samples from two healthy male human donors and from two male human donors with sickle cell disease were purchased from a commercial human blood cell supplier (Bioreclamation, New York, NY).

*In vitro* enzymatic LDX metabolism assay {#S0006-S2002}
-----------------------------------------

To examine the time course of LDX enzymatic metabolism, aliquots (5 mL, in duplicate) of human whole blood were incubated with 50 µL of LDX stock solution (100 µg/mL, leading to a final concentration of 1 µg/mL) at 37°C for 0.0, 0.25, 0.5, 1.0, 2.0, and 4.0 h. Negative control aliquots containing 5 mL 0.1 M phosphate buffer and 50 µL LDX stock solution were incubated in parallel. Incubation reactions were terminated by the addition of chilled acetonitrile (0.5 mL). All samples were extracted by protein precipitation using acetonitrile. Samples were then analyzed and quantified in duplicate for LDX and d-amphetamine using a validated liquid chromatographic mass spectrometric (LC/MS/MS; Triple Quadrupole MS API4000; Applied Biosystems, Sciex; at QPS, LLC, Newark, DE) method.

Results {#S7}
=======

Healthy vs sickle cell disease in human whole blood samples {#S0007-S2001}
-----------------------------------------------------------

The percentages of initial LDX concentration remaining during the 4-h incubation with whole blood from healthy donors and donors with sickle cell disease are illustrated in [Figures 1a and b](#F0001){ref-type="fig"}, respectively. At time 0, individual mean LDX concentrations were 823.1 and 668.3 ng/mL for the samples from healthy donors, and 996.0 and 1001.0 ng/mL for the samples from donors with sickle cell disease. After 4 h incubation, individual mean LDX concentrations were 107.6 and 70.0 ng/mL for the samples from healthy donors, and 140.0 and 152.8 ng/mL for the samples from donors with sickle cell disease. With blood from both healthy donors and sickle cell donors, LDX concentrations declined throughout the 4-h incubation period, such that, at 4 h, the LDX concentration had declined to less than 20% of the initial concentration (two healthy donors, 13.1% and 10.5%; two sickle cell donors, 14.1% and 15.3%). The half-life of LDX was 1.15 and 1.13 h for the healthy donors and 1.30 and 1.36 h for the donors with sickle cell disease.

![Percentage of initial lisdexamfetamine dimesylate (LDX) concentration during incubation with human whole blood.](ijda-2-17.01){#F0001}

[Figures 2a and b](#F0002){ref-type="fig"} illustrate the concentrations of d-amphetamine observed during the 4-h incubation with whole blood from healthy donors and donors with sickle cell disease, respectively. The d-amphetamine concentrations increased during incubation of LDX in blood samples from both healthy and sickle cell donors. At 4 h, mean d-amphetamine levels detected by LC/MS/MS were 297.0 ng/mL and 324.3 ng/mL in the two healthy donors and 304.5 ng/mL and 286.6 ng/mL in the two sickle cell donors.

![d-Amphetamine concentration during incubation of lisdexamfetamine dimesylate (LDX) with human whole blood.](ijda-2-17.02){#F0002}

Discussion {#S8}
==========

In whole blood samples collected from healthy human subjects, hydrolysis of LDX to d-amphetamine was robust. Hydrolysis of LDX was unaffected by RBC sickle cell pathology; the timing and magnitude of LDX metabolism to active d-amphetamine were similar in whole blood samples from donors with or without sickle cell disease.

The current investigation provides support for earlier findings^[@C1]^ that the human RBC is an important site of LDX biotransformation to d-amphetamine. In whole blood samples, *in vitro* hydrolysis of LDX to d-amphetamine was robust and unaffected by sickle cell RBC pathology in the current study. Prior *in vitro* work has shown that the rate of LDX hydrolysis is reduced only when RBC concentration is reduced to 10% of normal hematocrit^[@C1]^. One might predict from these *in vitro* findings that LDX and d-amphetamine pharmacokinetics in patients with sickle cell disease may be similar to that seen in healthy individuals. In line with this hypothesis, *in vitro* clearance of LDX was similar in blood samples from both healthy and sickle cell donors reported in this study. Nevertheless, there are other sites of pathology in sickle cell disease beyond the RBC (such as the renal system) that may affect LDX clearance. To examine the potential effect of these *in vitro* findings in the clinical setting, it is necessary to directly determine the pharmacokinetics of LDX and d-amphetamine in clinical trials that enroll human participants with sickle cell disease.

It will also be of interest to identify more precisely the mechanism by which RBCs metabolize LDX. Current and previous findings suggest that whichever enzyme(s) are involved, this must be a high-capacity system that is not affected by calcium-dependent enzymes^[@C1]^ and may not be significantly altered in settings in which RBC pathology exists. Structurally, LDX may be considered to be a dipeptide and, similar to other such molecules, may interact with transporters, channels, or receptors on RBC membranes^[@C9]^.

Prior research has shown that RBCs actively transport catecholamine compounds, such as dopamine, into the cell^[@C10]^, which d-amphetamine resembles structurally, putatively via the choline exchange system. Alternately, since RBC surface glycoproteins enzymatically process peptides^[@C9]^, LDX may interact with these glycoproteins. Investigation of major RBC enzyme pathways and transporter proteins may be warranted to identify the primary mechanism of LDX biotransformation at this site.

Limitations {#S0008-S2001}
-----------

The current findings are derived from *in vitro* investigations on a small number of samples and conducted using commercially obtained blood specimens. The applicability of data from this *in vitro* experimental system to *in vivo* function has not been established. In this study, 4-h LDX blood concentrations in samples from normal donors and those with sickle cell disease were higher than peak plasma concentrations seen in pharmacokinetic studies of healthy volunteers administered doses within the therapeutic range^[@C4]^. Biotransformation at lower concentrations has not been studied.

Conclusions {#S9}
===========

The *in vitro* biotransformation of LDX to l-lysine and d-amphetamine is similar in human blood from normal donors and those with sickle cell disease. These findings confirm previous results that RBCs are an important site of LDX metabolism in humans. Although the results suggest that the process may be unaffected by sickle cell pathology, it should be noted that *in vitro* studies are not always predictive of the *in vivo* situation, and these findings should be confirmed in clinical studies that include individuals with sickle cell disease. While short- and long-term efficacy and safety of LDX has been characterized in studies in children and adults with ADHD^[@C11]^, further investigation is needed to identify the precise erythrocyte mechanism(s) involved.
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[^1]: These data were presented, in part, at the 50th Annual New Clinical Drug Evaluation Unit Meeting, June 14--17, 2010, in Boca Raton, FL.
